Generic metronidazole vaginal gel is not one universally interchangeable product. In the United States, vaginal metronidazole is available in multiple concentrations and presentations; generic approval is evaluated against a specific reference drug. In particular, the common 0.75% vaginal gel category is distinct from the 1.3% single-dose presentation associated with Nuvessa. The vaginal route hub introduces these product families; this page explains the generic and brand relationships.
For generic 0.75% gel, pharmacists compare the approved product details and permitted substitution status rather than assuming all brands and tubes are identical. A less obvious regulatory fact is that FDA approved Encube metronidazole vaginal gel 1.3% under ANDA 216795 in March 2024 as therapeutically equivalent to Nuvessa. A corresponding 1.3% generic label appears in DailyMed. The existence of this approval corrects outdated articles claiming that no U.S. Nuvessa generic has ever been approved.
Approval does not mean every pharmacy currently offers that product, nor does it mean 0.75% and 1.3% can be swapped. This page focuses on reading FDA records, distinguishing reference drugs and confirming the exact vaginal gel identified on a prescription. For purchasing logistics, consult the vaginal gel buying guide.
The FDA generic pathway requires demonstration of relevant pharmaceutical and therapeutic equivalence to a reference product, including route of administration, dosage form and strength. Labeler names, package graphics and permissible inactive ingredients can differ. What matters is the regulatory comparison for the specified prescription product, not whether two advertisements use the word metronidazole.
For 0.75% intravaginal gel, an approved generic can be evaluated relative to the appropriate reference product. A separate generic approval for 1.3% exists, but that product is tied to its own reference drug and dosing presentation. The pharmacist remains responsible for determining what may be dispensed under the prescription and applicable law.
| Product listing | Generic/brand relationship | Substitution caution |
|---|---|---|
| 0.75% vaginal gel | Generic products and brands such as Vandazole | Check same concentration, route and approved equivalence |
| Nuvessa 1.3% | Single-dose branded reference product | Do not substitute 0.75% gel by arithmetic |
| Generic vaginal gel 1.3% | FDA-approved ANDA product referencing Nuvessa | Approval does not confirm stock or affordability |
| 0.75% topical skin gel | Different dermal drug product family | Never use as vaginal product |
In March 2024, FDA approved an abbreviated application for metronidazole vaginal gel 1.3% from Encube Ethicals. The approval letter explicitly states that FDA determined the product to be bioequivalent and therapeutically equivalent to Nuvessa vaginal gel 1.3%. The DailyMed label lists the 1.3% generic as an ANDA product and identifies the vaginal route and prefilled applicator presentation.
This is a regulatory fact, not an advertisement for a particular seller. Pharmacy supply, patent questions, distribution arrangements and insurance decisions are different matters. Claims that Nuvessa categorically has no approved generic are outdated, while claims that every pharmacy can supply the generic immediately would also be unsupported.
Vandazole is a named 0.75% intravaginal product; approved generic metronidazole vaginal gel 0.75% products have their own labeling and identifiers. A pharmacy can compare an exact prescription with authorized presentations and, when appropriate, check the FDA Orange Book. Not every brand reference, marketing label or carton size proves that two products have the same approved application or substitution code.
The Vandazole product page provides the branded context and the 0.75% vaginal gel guide focuses on the formulation itself. This page should be used for equivalence questions rather than as a claim about brand availability.
FDA's Orange Book provides application and therapeutic-equivalence records; DailyMed hosts structured drug labels; the NDC Directory contains product listing information submitted by labelers. They answer related but different questions. An NDC can help identify what a pharmacy says it is dispensing, but FDA warns that simply having an NDC does not establish that a product is FDA-approved.
None of these resources serves as a live pharmacy shelf monitor. If a database lists a product with an old or active marketing record, call the actual dispensing pharmacy and identify the package before relying on it. The availability-check guide explains the operational steps.
Both 0.75% and 1.3% vaginal gels contain metronidazole, but their concentration, delivery systems and labeled regimens differ. The generic designation within one strength does not confer permission to use a different concentration, double an applicator amount or transfer patient instructions between products.
The comparison Nuvessa versus Vandazole covers the distinctions between branded presentations. If a pharmacy proposes a product other than the one written, ask the pharmacist whether it is an authorized same-product equivalent or whether the prescriber needs to modify the prescription.
A generic can be pharmaceutically appropriate while differing in carton artwork, manufacturer, labeling presentation or permissible inactive ingredients. Patients with allergies or prior reactions should ask about the exact formulation. For a vaginal product, the applicator and delivery presentation deserve particular attention because the patient may be relying on written instructions tied to the supplied device.
Compare the prescription label with the product carton and any enclosed instructions. If a product is repackaged or the labeler name differs from the manufacturer, the pharmacist can explain the relationships rather than asking the patient to identify the company by an internet image.
Generics often change the available purchasing options, but generic status is not an individual price quote. A cash-pay amount can depend on the exact package, pharmacy, dispensing fees, plan rules, network and stock position. A branded product might appear differently on an insurer formulary, and a generic may still require verification before a pharmacy can order it.
The vaginal gel cost guide explains how to compare like-for-like prescriptions. Do not choose 0.75% in place of 1.3% merely to access a lower price.
FDA equivalence information concerns the pharmaceutical product, not diagnosis. Bacterial vaginosis may require clinician evaluation, and similarly presenting symptoms can indicate yeast infections, trichomoniasis or another condition. Vaginal metronidazole gel is not recommended to treat trichomoniasis, irrespective of whether it is branded or generic.
For clinical context, see metronidazole for BV. For the specific act of obtaining a prescription, see vaginal metronidazole prescriptions.
Drug approval timelines do not stand still. Some older reference pages describe Nuvessa as a brand without an approved generic, but FDA's March 2024 ANDA 216795 approval letter records an equivalent 1.3% generic, and DailyMed contains a later product label. A current regulatory check is therefore necessary before making categorical statements about generic status.
The approval letter and subsequent labeling are stronger evidence of regulatory identity than an undated retailer summary. Nevertheless, this does not establish how many pharmacies stock the product or what price a particular plan will charge. Distinguishing documented approval from commercial distribution avoids misleading readers in either direction.
A patient can ask the pharmacist: which reference product does this generic correspond to, is the concentration identical, is the dosage form intravaginal gel, and does the package include the required applicator? The pharmacist can also explain any differences in brand labeling, inactive ingredients and patient directions.
These questions do not require the patient to independently interpret an Orange Book equivalence code. They make it easier to obtain a professional, documented answer. If a proposed alternative changes the treatment course or concentration, the prescriber should be involved instead of approving the change through an online cart selection.
Read the exact prescription for vaginal route, concentration, directions and quantity. Ask the pharmacist to identify the generic's approval status and reference product if a substitution is proposed; confirm whether the applicator packaging and patient instructions will change. Check that the dispensing label matches what the clinician ordered.
If the generic is not available, ask the pharmacy to contact the clinician about lawful alternatives or another dispensing location. A substitution decision is never established by a price comparison, search result or a database screenshot.
Yes. U.S. approvals include generic 0.75% vaginal products and a separately approved 1.3% generic.
Yes. FDA approved Encube ANDA 216795 in March 2024 and determined it therapeutically equivalent to Nuvessa 1.3%.
No. Approval identifies a regulatory status; pharmacies must confirm actual availability and ordering options.
Not as a same-strength generic substitution. They have different concentrations and labeled presentations; discuss any change with the prescriber.
Vandazole is a branded 0.75% vaginal metronidazole product. Other companies may market approved generic 0.75% gel.
It refers to FDA evaluation of a generic relative to a specified reference product under the applicable standards; it is not a universal interchangeability claim across forms.
Not necessarily. Appearance, packaging and permitted inactive ingredients can vary.
No. FDA states that NDC assignment and directory inclusion are not proof of agency approval.
Yes. Ask the pharmacist what approved products correspond to the prescription and whether substitution is allowed.
Yes. Generic vaginal metronidazole products remain prescription medicines in the United States.